FCE 22250

Known as: FCE-22250, Rifamycin, 3-(methyl(1-piperidinylmethylene)hydrazino)- 
 

Topic mentions per year

Topic mentions per year

1983-1994
01219831994

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1994
Review
1994
The number of cases with tuberculosis is again increasing in many countries, and recently several nosocomial outbreaks of… (More)
Is this relevant?
1991
1991
After rats being given ig FCE 22250 5, 10 and 25 mg.kg-1, the plasma peak times (Tmax) were 12-14 h, the max plasma… (More)
Is this relevant?
1988
1988
Thirty-eight strains of Haemophilus ducreyi isolated in southern Africa were tested in vitro against 15 antimicrobial agents… (More)
Is this relevant?
1988
1988
The susceptibility of 119 strains of Neisseria gonorrhoeae isolated in Munich in 1986 to eight antibiotics was assessed. Although… (More)
Is this relevant?
1987
1987
The in vitro activities of rifampicin and the new rifamycin FCE 22250 were evaluated against the intracellular pathogens… (More)
Is this relevant?
1987
1987
The bactericidal activity of six new rifamycin derivatives--rifabutin (RBU), FCE 22250 (F22), rifapentine (RPE), CGP 29861 (C29… (More)
Is this relevant?
1985
1985
FCE 22250 (3-(N-piperidinomethylazino)methylrifamycin SV) is a member of the new class of 3-azinomethylrifamycins characterized… (More)
Is this relevant?